GnRH analogs versus expectant management in minimal and mild endometriosis-associated infertility

Riccardo Marana, Marana R, R Marana, Paielli FV, FRANCESCO V. PAIELLI, F V Paielli, Ludovico Muzii, Muzii L, L Muzii, Dell'Acqua S, S Dell'Acqua, Stefano Mancuso, S Mancuso, Mancuso S
Acta Europaea fertilitatis · 1995 · vol. 25(1) , pp. 37–41 · PMID:7887079 · W2640867
Other OA: closed CC0 ⤵ 8 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This study found comparable pregnancy rates between GnRH analog treatment and expectant management in infertile patients with minimal and mild endometriosis, suggesting expectant management is more cost-effective.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The aim of the present study is to compare the outcome of GnRH analog treatment versus expectant management in infertile patients with minimal and mild endometriosis. From January 1987 to December 1990, 14 patients with stage I and II endometriosis underwent a six-month course of the GnRH analog buserelin, whereas 38 patients underwent expectant management. The two groups were comparable as to mean age of the patients, mean length of infertility prior to diagnosis and mean scores of endometriosis. No major tubal or male factor of infertility was present in any patient. Cumulative pregnancy rates at 12 months were comparable in the two groups (48% for GnRH analog treatment and 42% for expectant management). Expectant management should therefore be considered the most cost-effective option in the management of mild endometriosis-associated infertility.

My notes (saved in your browser only)

Condition tags

endometriosisinfertility

MeSH descriptors

Buserelin Endometriosis Infertility Buserelin Buserelin Buserelin Endometriosis Endometriosis Female Female Humans Humans Infertility Infertility Infertility Pregnancy Pregnancy

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

Cited by (8)

Source provenance

europepmc
last seen: 2026-10-11T09:27:45.537177+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-10-08T21:59:07.256998+00:00
License: CC0 · commercial use OK